Every 8-K that Illumina Inc (ILMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ILMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ILMN filings page.
Illumina, Inc. reported completion of a public debt offering of $300,000,000 aggregate principal amount of 4.950% notes due 2029. The notes were issued under an existing Indenture with U.S. Bank Trust Company, National Association, and were registered on a Form S-3 shelf registration.
Illumina expects to use the net proceeds from this offering, together with cash on hand, to repay its 4.650% notes due September 9, 2026, of which $500 million aggregate principal amount was outstanding as of June 28, 2026. The new notes accrue interest at 4.950% per annum, payable semi-annually, and mature on September 19, 2029. The company may redeem the notes, in whole or in part, at specified redemption prices and on terms set forth in the note documentation, and the notes may be accelerated upon an Event of Default as defined in the Indenture.
Illumina, Inc. entered into a new $1,000 million senior unsecured revolving credit facility with a syndicate of lenders and Bank of America, N.A. as administrative agent, issuing bank and swingline lender. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit.
Borrowings will bear a variable interest rate based on term SOFR or an alternate base rate, plus a margin that varies with Illumina’s debt rating. The agreement permits Illumina, subject to lender consent and conditions, to increase commitments or add term loans by up to $500 million. The facility matures on August 13, 2031 and may be extended for up to three additional one-year periods. It contains a maximum total leverage ratio covenant and operating covenants limiting subsidiary indebtedness, liens, fundamental changes and asset dispositions. Amounts may be prepaid and commitments terminated at any time without premium or penalty, and there were no borrowings outstanding as of the date referenced. This facility replaces and terminates the company’s prior 2023 credit agreement.
Illumina, Inc. entered into an underwriting agreement to issue and sell $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The transaction is with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., acting as representatives of the underwriters, and is expected to close on August 17, 2026, subject to customary closing conditions.
Illumina expects to use the net proceeds from these notes, together with cash on hand, to repay its 4.650% notes due September 9, 2026. The new notes will be issued under an effective shelf Registration Statement on Form S-3 (No. 333-281921). The detailed underwriting agreement is included as an exhibit and incorporated by reference.
Illumina, Inc. describes a proposed resolution of Delaware litigation brought by Icahn Partners LP and related plaintiffs challenging the company’s approximately $8 billion acquisition of GRAIL, Inc. Illumina and current and former directors entered a Release Agreement on August 21, 2025, providing mutual releases with no payments by any party.
Under the agreement, the action Icahn Partners LP v. deSouza will be dismissed with prejudice as to those plaintiffs only and without prejudice to all other Illumina stockholders, including plaintiffs in three separate derivative actions that remain pending. The Delaware Court of Chancery will hold a hearing on the proposed dismissal on November 2, 2026, at 1:30 p.m. Eastern time. Stockholders of record on April 3, 2023 and current stockholders as of July 31, 2026 receive notice and may object under specified procedures. Defendants continue to deny the plaintiffs’ claims, and the court has made no findings on the merits.
Illumina, Inc. reported second-quarter 2026 revenue of $1.16 billion, up 9.5% from Q2 2025, with rest-of-world organic revenue growth of 8.1%. GAAP operating margin was 21.1% and non-GAAP operating margin was 22.5%.
GAAP diluted EPS was $1.35 compared with $1.49 a year earlier; non-GAAP diluted EPS was $1.31 compared with $1.19. Free cash flow was $162 million versus $204 million, and cash, cash equivalents and short-term investments totaled $1.17 billion at quarter-end.
For fiscal 2026, Illumina now expects total revenue of $4.60–$4.64 billion, rest-of-world organic revenue growth greater than 5%, non-GAAP operating margin of 23.4%–23.6%, and non-GAAP diluted EPS of $5.30–$5.40.
Illumina, Inc. increased its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D. as a director, effective June 16, 2026. He will stand for election at the company’s 2027 annual meeting of stockholders for a one-year term.
Dr. Skovronsky is deemed an independent director under applicable Nasdaq and SEC rules and will participate in Illumina’s non-employee director compensation programs. He currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing deep experience in drug discovery, clinical development, and translational medicine relevant to Illumina’s genomics and multiomics platforms.
Illumina, Inc. reported the final voting results from its 2026 annual meeting of stockholders. Stockholders elected nine directors, ratified the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending January 3, 2027, and approved on an advisory basis the compensation of the company’s named executive officers.
There were 151,906,915 votes underlying issued and outstanding shares of common stock as of the March 26, 2026 record date. At the meeting, 141,044,031 votes were present in person or by proxy, representing 92.85% of the voting power entitled to vote, which constituted a quorum.
Illumina reported a solid first quarter of fiscal 2026 and increased its full-year outlook. Q1 2026 revenue was $1.09 billion, up 4.8% from Q1 2025, with GAAP operating margin improving to 19.2% and non-GAAP operating margin to 21.9%. GAAP diluted EPS rose to $0.87 from $0.82, while non-GAAP diluted EPS increased to $1.15 from $0.97.
Free cash flow was $251 million, up from $208 million, and cash flow from operations reached $289 million. For fiscal 2026, Illumina now guides to $4.52–$4.62 billion in revenue and non-GAAP EPS of $5.15–$5.30. The board also authorized a new share repurchase program of up to $1.5 billion, on top of $314 million remaining under a prior $1.5 billion authorization.
Illumina, Inc. announced upcoming changes to its Board of Directors, with three current members planning to retire at the 2026 annual meeting of stockholders.
Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire effective May 21, 2026, and the company states their retirements are not due to any dispute or disagreement with the company or its Board.
The Board has nominated David P. King, a former CEO and Executive Chairman of Laboratory Corporation of America with extensive healthcare and life sciences board experience, to stand for election as a director at the 2026 annual meeting.
Illumina, Inc. filed a Form 8-K to furnish a press release announcing its financial results for the fourth quarter and fiscal year ended December 28, 2025. The press release is provided as Exhibit 99.1 under Item 2.02, Results of Operations and Financial Condition, and is treated as furnished rather than filed.
The filing also lists Exhibit 104 for the cover page interactive data file embedded in the Inline XBRL document. The report is signed on behalf of Illumina by Chief Financial Officer Ankur Dhingra.
Illumina, Inc. has completed its previously announced acquisition of Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic and Sengenics group companies. The deal closed on January 30, 2026.
Illumina paid a cash purchase price of $350,000,000, subject to customary adjustments, and agreed to provide Standard BioTools with royalty streams and up to $75,000,000 in potential milestone payments tied to revenues from certain products and services. The acquired business includes KREX, Single SOMAmer, and related translational and diagnostic assays, and excludes Standard BioTools’ mass cytometry and microfluidics operations.
Illumina, Inc. reported that it has released a press release with unaudited preliminary financial results for its fourth quarter and full fiscal year ended December 28, 2025. The company furnished this update in connection with a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco.
The webcast is available through Illumina’s Investor Relations website and will remain accessible for at least 30 days. The press release is furnished as Exhibit 99.1 to this report and is treated as furnished, not filed, which limits how it is incorporated into other regulatory documents.
Illumina, Inc. reported that its Chief Commercial Officer, Everett Cunningham, has notified the company that he will resign effective January 16, 2026. The notice was given on January 4, 2026, and the change was disclosed in connection with a current report on Form 8-K.
The company also issued a press release on January 8, 2026 describing management changes, including Cunningham’s resignation, which is included as an exhibit to the report.
Illumina, Inc. (ILMN) completed a public debt offering of $500,000,000 aggregate principal amount of 4.750% notes due 2030. These Notes pay interest semi-annually and mature on December 12, 2030.
Illumina expects to use the net proceeds for general corporate purposes, which may include repaying its 5.800% notes due December 12, 2025, of which $500 million was outstanding as of September 28, 2025, and helping fund the proposed acquisition of SomaLogic, Inc., along with related fees and expenses.
The Notes were issued under an existing Indenture with U.S. Bank Trust Company, National Association, and include customary terms such as Events of Default and the company’s ability to redeem the Notes in whole or in part at specified redemption prices.
Illumina, Inc. entered an underwriting agreement to issue and sell $500,000,000 aggregate principal amount of 4.750% notes due 2030. The offering is expected to close on November 25, 2025, subject to customary closing conditions.
Illumina expects to use the net proceeds for general corporate purposes, which may include repayment of its 5.800% notes due December 12, 2025 and completing the proposed acquisition of SomaLogic, Inc., including related fees and expenses. The notes will be issued off Illumina’s Form S‑3 shelf (No. 333-281921).
Illumina, Inc. filed a Form 8-K to note that it issued a press release announcing its financial results for the third quarter ended September 28, 2025. The press release itself is provided as Exhibit 99.1 and contains the detailed numbers and commentary for the period.
The filing clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished rather than filed under the Exchange Act, which limits certain legal liabilities and incorporation by reference into other securities filings. The document is signed on behalf of Illumina by Chief Financial Officer Ankur Dhingra.
Illumina has entered into a significant Stock Purchase Agreement with Standard BioTools to acquire SomaLogic and Sengenics entities for $350 million in cash, plus potential milestone payments of up to $75 million. The deal, announced June 22, 2025, includes Standard BioTools' aptamer-based and functional proteomics business, featuring KREX and Single SOMAmer technologies.
Key transaction details:
- Purchase includes SomaLogic Inc, Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd
- Deal includes transition services and license agreements
- Closing deadline set for March 23, 2026, with three possible 3-month extensions
- $14.5 million termination fee if deal fails due to regulatory clearance issues
The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Act clearance and regulatory approvals. This strategic acquisition significantly expands Illumina's presence in the proteomics market, though the company notes several risk factors including integration challenges and market uncertainties.